On October 20, 2023, the board of directors of Quince Therapeutics, Inc. appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition. Mr. Benatti was designated as a Class II director whose term expires at the Company?s 2024 Annual Meeting of Stockholders.